Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 9/20 | 0.88 |
| ▸ | CA12 | O43570 | 9/20 | 0.76 |
| ▸ | CA1 | P00915 | 9/20 | 0.76 |
| ▸ | CA2 | P00918 | 9/20 | 0.76 |
| ▸ | CA4 | P22748 | 9/20 | 0.76 |
| ▸ | CA9 | Q16790 | 9/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evatanepag SCHEMBL29376960 | 0.94 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL533264 | 0.94 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147493 | 0.94 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147496 | 0.93 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147494 | 0.93 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147489 | 0.93 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276385 | 0.92 | PTGER2 (0.84) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6278874 | 0.92 | PTGER2 (0.87) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6283458 | 0.91 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276293 | 0.91 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | claimed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | ABAT, BCAT2, PC | PTGER2 3715/4885CA12 2546/4885CA1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.